Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2026
The Safety of Perioperative Liposomal Bupivacaine Injections in Dermatologic Surgery Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rames Melissa M, Rios-Duarte Jorge A, Vidal Nahid Y
Аннотация
BACKGROUND: There is a paucity of literature investigating the use of liposomal bupivacaine (LB) in a dermatologic surgery setting.
OBJECTIVE: To identify the treatment characteristics and adverse events, including Local Anesthetic System Toxicity (LAST), in patients receiving perioperative LB.
MATERIALS AND METHODS: A retrospective chart review was performed at a single institution using an institutional database and key words "Exparel" or "liposomal bupivacaine." Patients ≥18 years old who received perioperative LB to the surgical site and surrounding skin were included.
RESULTS: A total of 140 LB administrations and 129 patients were included. Liposomal bupivacaine was used most often in the setting of excisions ( n = 88, 62.9%) and Mohs micrographic surgery ( n = 49, 35%), with hidradenitis suppurativa ( n = 77, 55%) and cutaneous neoplasms ( n = 56, 40%) the most frequent diagnoses. The median postoperative area and length were 23.6 cm 2 and 15.4 cm, respectively. The median LB dosage was 20 mL (range 1.5-20). There were no adverse events in 134 out of 136 patients of LB administration (98.5%). There were 2 reports (1.5%) of nausea on POD1 while these patients were taking opioids.
CONCLUSION: Liposomal bupivacaine should be considered for postoperative analgesia in patients undergoing dermatologic surgery because it is well tolerated and efficacious. The authors observed no cases of LAST.
OBJECTIVE: To identify the treatment characteristics and adverse events, including Local Anesthetic System Toxicity (LAST), in patients receiving perioperative LB.
MATERIALS AND METHODS: A retrospective chart review was performed at a single institution using an institutional database and key words "Exparel" or "liposomal bupivacaine." Patients ≥18 years old who received perioperative LB to the surgical site and surrounding skin were included.
RESULTS: A total of 140 LB administrations and 129 patients were included. Liposomal bupivacaine was used most often in the setting of excisions ( n = 88, 62.9%) and Mohs micrographic surgery ( n = 49, 35%), with hidradenitis suppurativa ( n = 77, 55%) and cutaneous neoplasms ( n = 56, 40%) the most frequent diagnoses. The median postoperative area and length were 23.6 cm 2 and 15.4 cm, respectively. The median LB dosage was 20 mL (range 1.5-20). There were no adverse events in 134 out of 136 patients of LB administration (98.5%). There were 2 reports (1.5%) of nausea on POD1 while these patients were taking opioids.
CONCLUSION: Liposomal bupivacaine should be considered for postoperative analgesia in patients undergoing dermatologic surgery because it is well tolerated and efficacious. The authors observed no cases of LAST.